Table 4.
Drugs that interact with abiraterone or enzalutamide
| Inducing drug | Inhibitory drug | Effects observed | Authors’ recommendations | References | |
|---|---|---|---|---|---|
| Abiraterone | Rifampicin | AUCinf decreased (45 %) | Avoid combination if possible If not possible, the dose of abiraterone acetate should be increased to 1000 mg bid |
[14, 22, 25] | |
| Ketoconazole | AUCinf increased (15 %) | Not clinically relevant | [14, 22, 25] | ||
| Enzalutamide + N-desmethyl enzalutamide | Rifampicin | AUCinf decreased (37 %) | Switch to alternatives that are not inducers of CYP3A4 If not possible, the dose of enzalutamide should be increased to 240 mg once daily |
[15, 20] | |
| Itraconazole | AUCinf increased (1.3-fold) | Not clinically relevant | [15, 20, 32] | ||
| Gemfibrozil | AUCinf increased (2.2-fold) | Switch to alternatives that are not inhibitors of CYP2C8 If not possible, the dose of enzalutamide should be reduced to 80 mg once daily |
[15, 20, 32] |
AUC inf area under the concentration–time curve from time zero to infinity, bid twice daily